Evidence map›Paper›PMID 32198618›Full record

ArticleObesity surgery2020

Improvement of Cardiac Function After Roux-en-Y Gastric Bypass in Morbidly Obese Patients Without Cardiac History Measured by Cardiac MRI.

Dennis de Witte, Leontine H Wijngaarden, Vera A A van Houten, Marinus A van den Dorpel, Tobias A Bruning, Erwin van der Harst, René A Klaassen, Roelf A Niezen

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06132477 (Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06132477 phase4recruitingstarted 2024, after this paper: background citation

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Ran2024Enrolled150Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Hypertension, Metabolic Syndrome, Morbid ObesityArmsGLP-1 receptor agonist
PMID 28266779PMID 36765019PMID 32656729PMID 21844879PMID 29551470PMID 29730732PMID 30315341PMID 31502183PMID 31666597PMID 32163341PMID 32785814PMID 34822391other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dennis de WitteDepartment of Radiology, Maasstad Hospital, Rotterdam, the Netherlands. d.dewitte@erasmusmc.nl.
Leontine H WijngaardenDepartment of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
Vera A A van HoutenDepartment of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
Marinus A van den DorpelDepartment of Internal Medicine, Maasstad Hospital, Rotterdam, the Netherlands.
Tobias A BruningDepartment of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
Erwin van der HarstDepartment of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
René A KlaassenDepartment of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
Roelf A NiezenDepartment of Radiology, Maasstad Hospital, Rotterdam, the Netherlands.
Maasstad Ziekenhuis · NLDeventer Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetabolic syndrome in patients with morbid obesity causes a higher cardiovascular morbidity, eventually leading to left ventricular hypertrophy and decreased left ventricular ejection fraction (LVEF). Roux-en-Y gastric bypass (RYGB) is considered the gold standard modality for treatment of morbid obesity and might even lead to improved cardiac function. Our objective is to investigate whether cardiac function in patients with morbid obesity improves after RYGB. MATERIALS AND

methodsIn this single center pilot study, 15 patients with an uneventful cardiac history who underwent RYGB were included from May 2015 to March 2016. Cardiac function was measured by cardiac magnetic resonance imaging (CMRI), performed preoperatively and 3, 6, and 12 months postoperative. LVEF and myocardial mass and cardiac output were measured.

resultsA total of 13 patients without decreased LVEF preoperative completed follow-up (mean age 37, 48.0 ± 8.8). There was a significant decrease of cardiac output 12 months postoperative (8.3 ± 1.8 preoperative vs. 6.8 ± 1.8 after 12 months, P = 0.001). Average myocardial mass declined by 15.2% (P < 0.001). After correction for body surface area (BSA), this appeared to be non-significant (P = 0.36). There was a significant improvement of LVEF/BSA at 6 and 12 months postoperative (26.2 ± 4.1 preoperative vs. 28.4 ± 3.4 and 29.2 ± 3.6 respectively, both P = 0.002). Additionally, there was a significant improvement of stroke volume/BSA 12 months after surgery (45.8 ± 8.0 vs. 51.9 ± 10.7, P = 0.033).

conclusionRYGB in patients with morbid obesity with uneventful history of cardiac disease leads to improvement of cardiac function.

Indexed as

Gastric BypassObesity, MorbidAdultBody Mass IndexFollow-Up StudiesHumansMagnetic Resonance ImagingMiddle AgedPilot ProjectsStroke VolumeTreatment OutcomeVentricular Function, LeftWeight LossBariatric surgeryCardiac magnetic resonance imagingLeft ventricular ejection fractionLeft ventricular massObesityRoux-en-Y gastric bypass

Identifiers

PMID32198618
PMCPMC7260259
OpenAlexW3012812920

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.